Lecap Asset Management Ltd. Acquires 44,409 Shares of Hologic, Inc. (NASDAQ:HOLX)

Lecap Asset Management Ltd. raised its holdings in shares of Hologic, Inc. (NASDAQ:HOLX) by 733.8% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 50,461 shares of the medical equipment provider’s stock after acquiring an additional 44,409 shares during the period. Hologic makes up 1.0% of Lecap Asset Management Ltd.’s holdings, making the stock its 5th largest position. Lecap Asset Management Ltd.’s holdings in Hologic were worth $3,638,000 as of its most recent SEC filing.

A number of other institutional investors also recently added to or reduced their stakes in the business. Wolff Wiese Magana LLC bought a new stake in shares of Hologic during the third quarter valued at about $25,000. General Partner Inc. acquired a new position in Hologic during the 4th quarter valued at about $26,000. First Horizon Advisors Inc. raised its position in shares of Hologic by 38.3% during the 3rd quarter. First Horizon Advisors Inc. now owns 484 shares of the medical equipment provider’s stock worth $39,000 after buying an additional 134 shares in the last quarter. Cromwell Holdings LLC lifted its stake in shares of Hologic by 330.2% in the 3rd quarter. Cromwell Holdings LLC now owns 542 shares of the medical equipment provider’s stock worth $44,000 after acquiring an additional 416 shares during the period. Finally, Covestor Ltd boosted its holdings in shares of Hologic by 23.8% in the third quarter. Covestor Ltd now owns 692 shares of the medical equipment provider’s stock valued at $56,000 after acquiring an additional 133 shares in the last quarter. Institutional investors and hedge funds own 94.73% of the company’s stock.

Insiders Place Their Bets

In other news, COO Essex D. Mitchell sold 24,856 shares of the stock in a transaction that occurred on Wednesday, December 4th. The shares were sold at an average price of $76.34, for a total value of $1,897,507.04. Following the completion of the sale, the chief operating officer now directly owns 27,957 shares of the company’s stock, valued at $2,134,237.38. This represents a 47.06 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Corporate insiders own 1.88% of the company’s stock.

Hologic Stock Down 10.1 %

Shares of NASDAQ:HOLX opened at $65.45 on Friday. The firm has a 50 day simple moving average of $72.63 and a 200 day simple moving average of $77.86. Hologic, Inc. has a 52 week low of $64.87 and a 52 week high of $84.67. The company has a debt-to-equity ratio of 0.49, a quick ratio of 3.03 and a current ratio of 3.69. The company has a market cap of $14.77 billion, a PE ratio of 19.65, a price-to-earnings-growth ratio of 2.35 and a beta of 0.98.

Hologic (NASDAQ:HOLX) last released its earnings results on Wednesday, February 5th. The medical equipment provider reported $1.03 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $1.02 by $0.01. Hologic had a return on equity of 19.79% and a net margin of 19.59%. As a group, research analysts expect that Hologic, Inc. will post 4.28 earnings per share for the current year.

Wall Street Analyst Weigh In

HOLX has been the topic of several recent analyst reports. William Blair reissued an “outperform” rating on shares of Hologic in a report on Thursday. Stephens reissued an “overweight” rating and issued a $84.00 price objective on shares of Hologic in a research note on Thursday. StockNews.com raised Hologic from a “hold” rating to a “buy” rating in a research note on Thursday, November 14th. Needham & Company LLC cut shares of Hologic from a “buy” rating to a “hold” rating and set a $90.00 price target on the stock. in a research report on Monday. Finally, Leerink Partners lowered shares of Hologic from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $80.00 to $75.00 in a research report on Thursday. Ten equities research analysts have rated the stock with a hold rating, seven have issued a buy rating and one has assigned a strong buy rating to the stock. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and an average target price of $85.77.

About Hologic

Hologic, Inc develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women's health through early detection and treatment. The company operates through four segments: Diagnostics, Breast Health, GYN Surgical, and Skeletal Health. It provides Aptima molecular diagnostic assays to detect the infectious microorganisms; Aptima viral load assays for Hepatitis B virus, Hepatitis C virus, human immunodeficiency virus, and human cytomegalo virus; Aptima bacterial vaginosis and candida vaginitis assays for the diagnosis of vaginitis; Aptima SARS-CoV-2 and Panther Fusion SARS-CoV-2 assays to detect SARS-CoV-2; ThinPrep System for cytology applications; and Rapid Fetal Fibronectin Test that assists physicians in assessing the risk of pre-term birth.